The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli-D randomized controlled trial.
Ming LiuWeijun GuLi ChenYan Bing LiHongyu KuangJianling DuAgustina AlvarezFelipe LauandElisabeth SouhamiJiewen ZhangWeiya XuQin DuYi-Ming Munull nullPublished in: Diabetes, obesity & metabolism (2024)
In Chinese people with T2D suboptimally controlled with OADs, once-daily iGlarLixi provided better glycaemic control with BW benefit and lower hypoglycaemia event rates versus IDegAsp.